• Human CXCL2/MIP-2 protein (Recombinant) (NO-tag) (STJP001849)

Human CXCL2/MIP-2 protein (Recombinant) (NO-tag) (STJP001849)

SKU:
STJP001849

Current Stock:
Host: Pichia
Reactivity: Human
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Recombinant-Human CXCL2/MIP-2-NO-tag protein was developed from pichia and has a target region of NO-tag. For use in research applications.
Formulation: Lyophilized from a 0.22 Mu m filtered solution of PBS, pH 7.4.
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: CXCL2
Gene ID: 2920
Uniprot ID: CXCL2_HUMAN
Immunogen Region: Ala35-Asn107
Immunogen: Recombinant Human CXCL2/MIP-2 Protein is produced by Pichia expression system. The target protein is expressed with sequence (Ala35-Asn107) of human CXCL2/MIP-2 (Accession #NP_002080.1) fused with no additional amino acid.
Function Produced by activated monocytes and neutrophils and expressed at sites of inflammation. Hematoregulatory chemokine, which, in vitro, suppresses hematopoietic progenitor cell proliferation. GRO-beta(5-73) shows a highly enhanced hematopoietic activity.
Protein Name C-X-C Motif Chemokine 2
Growth-Regulated Protein Beta
Gro-Beta
Macrophage Inflammatory Protein 2-Alpha
Mip2-Alpha Cleaved Into - Gro-Beta(5-73
Gro-Beta-T
Hematopoietic Synergistic Factor
Hsf
Sb-251353
Database Links Reactome: R-HSA-380108
Reactome: R-HSA-418594
Reactome: R-HSA-6783783
Cellular Localisation Secreted
Alternative Protein Names C-X-C Motif Chemokine 2 protein
Growth-Regulated Protein Beta protein
Gro-Beta protein
Macrophage Inflammatory Protein 2-Alpha protein
Mip2-Alpha Cleaved Into - Gro-Beta(5-73 protein
Gro-Beta-T protein
Hematopoietic Synergistic Factor protein
Hsf protein
Sb-251353 protein
CXCL2 protein
GRO2 protein
GROB protein
MIP2A protein
SCYB2 protein

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance